{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Direct Bilirubin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Creatine Kinase MB mass"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"25"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"34"}],"units":"Participants"}],"title":"Chloride"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"8"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"10"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"title":"Carbon dioxide content/Bicarbonate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"title":"C-Reactive protein"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"4"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"title":"Creatinine Clearance"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"High Density Lipids cholesterol"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"20"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"24"}],"units":"Participants"}],"title":"Lactate Dehydrogenase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Low Density Lipids cholesterol"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"15"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"}],"units":"Participants"}],"title":"Total Protein"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Troponin I"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Troponin T"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"}],"title":"Decrease Low"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"13"}],"title":"Increase to High"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"title":"Urea/BUN"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"39"}],"units":"Participants"}],"description":"For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject \"Decreased to Low\" and Increase to High\" during the post-baseline period. Only descriptive analysis.","groups":[{"description":"Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"OG000","title":"Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"OG001","title":"Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part D: Dabrafenib 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"OG003","title":"Part D: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.","reportingStatus":"POSTED","timeFrame":"From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)","title":"Part D: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range","type":"PRIMARY","unitOfMeasure":"Participants"}